[1] Meola M,Nalesso F,Petrucci I,et al. Clinical scenarios in acute kidney injury: hepatorenal syndrome.Contrib Nephrol,2016,188:33-38.
[2] Juan G A,Matthew E C,Hepatorenal syndrome: update on diagnosis and therapy. World J Hepatol,2017,6: 293-299.
[3] Fede G,D’Amico G,Arvaniti V,et al. Renal failure and cirrhosis: a systematic review of mortality and prognosis. J Hepatol,2012,4:810-818.
[4] Ginès P,Guevara M,Arroyo V,et al. Hepatorenal syndrome. Lancet,2003,9398:1819-1827.
[5] Wong LP,Blackley MP,Andreoni KA,et al. Survival of liver transplant candidates with acute renal failure receiving renal replacement therapy. Kidney Int,2005,1:362-370.
[6] European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol,2010,3:397-417.
[7] Angeli P,Ginès P,Wong F,et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites.J Hepa-tol,2015,4:968-974.
[8] Belcher JM. Acute kidney injury in liver disease: role of biomarkers.Adv Chronic Kidney Dis,2015,5:368-375.
[9] Belcher JM,Sanyal AJ,Peixoto AJ,et al. Kidney biomarkers and differential diagnosis of patients with cirrhosis and acute kidney injury.Hepatology,2014,2:622-632.
[10] Alessandria C,Ozdogan O,Guevara M,et al. MELD score and clinical type predict prognosis in hepatorenal syndrome: rele-vance to liver transplantation.Hepatology,2005,6:1282-1289.
[11] Wong F,Leung W,Al Beshir M,et al. Outcomes of patients with cirrhosis and hepatorenal syndrome type 1 treated with liver transplantation.Liver Transpl,2015,3:300-307.
[12] Brensing KA,Textor J,Perz J,et al. Long term outcome after transjugular intrahepatic portosystemic stentshunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study. Gut,2000,2:288-295.
[13] Pipili C,Cholongitas E. Renal dysfunction in patients with cirrhosis: where do we stand. World J Gastrointest Pharmacol Ther,2014,3:156-168.
[14] Keller F,Heinze H,Jochimsen F,et al. Risk factors and outcome of 107 patients with decompensated liver disease and acute renal failure (including 26 patients with hepatorenal syndrome): the role of hemodialysis. Ren Fail,1995,2:135-146.
[15] Olga Baraldi,Chiara Valentini,Gabriele Donati,et al. Hepatorenal syndrome: update on diagnosis and treatment. World J Nephrol,2015,5:511-520.
[16] Rifai K,Ernst T,Kretschmer U,et al. The Prometheus device for extracorporeal support of combined liver and renal failure. Blood Purif,2005,4:298-302.
[17] Mitzner SR,Stange J,Klammt S,et al. Extracorporeal detoxification using the molecular adsorbent recirculating system for critically ill patients with liver failure. J Am Soc Nephrol,2001,17:S75-S82.
[18] Sanyal AJ,Boyer T,Garcia-Tsao G,et al. A randomized,prospective,double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome.Gastroenterology,2008,5:1360-1368.
[19] Singh V,Ghosh S,Singh B,et al. Noradrenaline vs. terlipressin in the treatment of hepatorenal syndrome: a randomized study.J Hepatol,2012,6:1293-1298.
[20] Wang H,Liu A,BO W,et al. terlipressin in the treatment of hepatorenal syndrome: a systematic review and meta-analysis. Medicine(Baltimore),2018,97(16):e0431.
[21] Piano S,Angeli P. Dopamine and furosemide for the treatment of hepatorenal syndrome: a reappraisal or just smoke and mirrors.J Clin Exp Hepatol,2015,4:273-275.
[22] Cavallin M,Kamath PS,Merli M,et al. Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: a randomized trial.Hepatology,2015,2:567-574.
[23] Lachlan NJ,Semple SI,Patel D. Serelaxin increased renal blood flow in patients with cirrhosis and portal hypertension. AASLD Liver Meeting 2015.Hepatology,2015,62:S345A.
[24] Snowdon VK,Lachlan NJ,Hoy AM,et al. Serelaxin as a potential treatment for renal dysfunction in cirrhosis: Preclinical evaluation and results of a randomized phase 2 trial. PLoS Med,2017,14:e1002248. |
